The Life Raft Group is pleased to announce the release of the first issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to GIST.
The Life Raft Group is pleased to formally announce the creation of its first ever Global Medical Team. This team, which consists of leading physicians throughout the world, will provide the LRG the opportunity to [...]
From October 30th to November 2nd the Life Raft Group staff members attended the annual Connective Tissue Oncology Society (CTOS) Meeting in NYC.
The LRG Research Team recently held a teleconference that focused primarily on a study the team will collaborate on and intends to publish.
Drs. Jonathan Fletcher, of Brigham & Women’s Hospital, Harvard University and Maria Debiec-Rychter, of the Catholic University in Leuven, Belgium, members of the LRG Research Team were part of a recently published study that looked at the effectiveness of GDC-0941, a PI3K inhibitor when used in combination with imatinib (Gleevec).
Sutent is the second-line approved treatment for Gastrointestinal Stromal Tumor and is prescribed when treatment with the first-line drug, Gleevec (Imatinib) is no longer effective or cannot be tolerated. The two drugs work differently, so [...]
The Sarcoma Alliance for Research through Collaboration (SARC) in partnership with the National Cancer Institute (NCI) is currently recruiting patients for its Phase II trial (SARC-022) of Linsitinib (OSI-906), an IGF-1R inhibitor. Linsitinib is targeted [...]
Bayer recently announced the results of its Phase III trial for regorafenib (BAY 73-4506), which is designed for patients with metastatic and/or unresectable GIST that have failed both imatinib and sunitinib.
GIST is a disease with a number of subtypes, and is beginning to be increasingly viewed as a “family of diseases”. One particular form of the disease is commonly known as “Pediatric GIST” - in this form the mutation occurs when the patient is either a child or young adult (but may not be discovered until later).
A study of newly diagnosed CML patients concentrated on OCT-1 activity as a predictor of molecular response and progression-free survival (PFS) treated with imatinib.